Endo Gains Control of Two Collagenase Therapies in BioSpecifics Purchase
Endo International announced that it will purchase the biopharmaceutical company BioSpecifics Technologies for approximately $540 million giving the company complete control over two promising collagenase-based therapies. Source: Drug Industry Daily